The ORR showed a trend toward sorafenib with erlotinib at 6.6% vs. 3.9% [ 116 ].
also in 53,322 other papers
Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.